JO3101B1 - مشتقات بنزوثيازول كعوامل مضادة للسرطان - Google Patents

مشتقات بنزوثيازول كعوامل مضادة للسرطان

Info

Publication number
JO3101B1
JO3101B1 JOP/2009/0448A JOP20090448A JO3101B1 JO 3101 B1 JO3101 B1 JO 3101B1 JO P20090448 A JOP20090448 A JO P20090448A JO 3101 B1 JO3101 B1 JO 3101B1
Authority
JO
Jordan
Prior art keywords
anticancer agents
benzothiazole derivatives
benzothiazole
derivatives
symbol
Prior art date
Application number
JOP/2009/0448A
Other languages
English (en)
Inventor
Takagi Terufumi
Hirose Masaaki
Okaniwa Masanori
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42026212&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3101(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Application granted granted Critical
Publication of JO3101B1 publication Critical patent/JO3101B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Abstract

يتعلق الاختراع الحالي بمشتق heterocycle ملتحم (fused heterocycle derivative) يظهر نشاط قوي يثبط Raf. يتعلق الاختراع الحالي أيضا بالمركب (compound) المتمثل في الصيغة: حيث يكون كل رمز كما تحدد في المواصفة الحالية، أو ملح (salt) منه
JOP/2009/0448A 2008-12-02 2009-11-25 مشتقات بنزوثيازول كعوامل مضادة للسرطان JO3101B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008307581 2008-12-02
JP2009125256 2009-05-25

Publications (1)

Publication Number Publication Date
JO3101B1 true JO3101B1 (ar) 2017-09-20

Family

ID=42026212

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2009/0448A JO3101B1 (ar) 2008-12-02 2009-11-25 مشتقات بنزوثيازول كعوامل مضادة للسرطان

Country Status (41)

Country Link
US (2) US8143258B2 (ar)
EP (1) EP2358689B9 (ar)
JP (1) JP5640014B2 (ar)
KR (1) KR101639092B1 (ar)
CN (1) CN102300854B (ar)
AR (1) AR074435A1 (ar)
AU (1) AU2009323274B2 (ar)
BR (1) BRPI0922109A2 (ar)
CA (1) CA2745144C (ar)
CL (1) CL2011001299A1 (ar)
CO (1) CO6400140A2 (ar)
CR (1) CR20110366A (ar)
CY (1) CY1117178T1 (ar)
DK (1) DK2358689T5 (ar)
DO (1) DOP2011000165A (ar)
EA (1) EA019447B1 (ar)
EC (1) ECSP11011165A (ar)
ES (1) ES2557304T3 (ar)
GE (1) GEP20146003B (ar)
HK (1) HK1161236A1 (ar)
HR (1) HRP20151370T1 (ar)
HU (1) HUE026491T4 (ar)
IL (1) IL213184A0 (ar)
JO (1) JO3101B1 (ar)
MA (1) MA32911B1 (ar)
ME (1) ME02331B (ar)
MX (1) MX2011005836A (ar)
MY (1) MY150989A (ar)
NZ (1) NZ593759A (ar)
PE (1) PE20110588A1 (ar)
PL (1) PL2358689T3 (ar)
PT (1) PT2358689E (ar)
RS (1) RS54370B9 (ar)
SG (1) SG171426A1 (ar)
SI (1) SI2358689T1 (ar)
SM (1) SMT201500316B (ar)
TN (1) TN2011000280A1 (ar)
TW (1) TWI436987B (ar)
UY (1) UY32281A (ar)
WO (1) WO2010064722A1 (ar)
ZA (1) ZA201104659B (ar)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2008001626A1 (es) * 2007-06-05 2009-06-05 Takeda Pharmaceuticals Co Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer.
US8324395B2 (en) * 2007-08-23 2012-12-04 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US8445509B2 (en) * 2008-05-08 2013-05-21 Takeda Pharmaceutical Company Limited Fused heterocyclic derivatives and use thereof
JP5579619B2 (ja) 2008-12-01 2014-08-27 武田薬品工業株式会社 複素環化合物およびその用途
WO2013138753A1 (en) 2012-03-16 2013-09-19 Fox Chase Chemical Diversity Center, Inc. Prodrugs of riluzole and their method of use
JP2015511632A (ja) * 2012-03-30 2015-04-20 武田薬品工業株式会社 メラノーマの治療におけるｒａｆ阻害剤およびｍｅｋ阻害剤の投与
DK2888010T3 (da) 2012-08-22 2021-06-28 Univ Cornell Fremgangsmåder til at hæmme fascin
JP6380862B2 (ja) 2013-06-28 2018-08-29 ベイジーン リミテッド 複数種類のキナーゼの阻害剤としての縮合三環式アミド系化合物
NZ716392A (en) 2013-06-28 2017-03-31 Beigene Ltd Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors
CN103435572B (zh) * 2013-07-16 2015-02-04 浙江医药高等专科学校 噻唑并环己烷类化合物、其制备方法和抗肿瘤用途
CN103435573B (zh) * 2013-07-16 2015-04-01 浙江医药高等专科学校 苄基取代的噻唑并环己烷类化合物、其制备方法和用途
CN103408541B (zh) * 2013-07-16 2015-04-01 浙江医药高等专科学校 吲哚取代的噻唑并环己烷类化合物、及其抗肿瘤用途
CN103382190B (zh) * 2013-07-16 2015-01-14 浙江医药高等专科学校 一类噻唑并环己烷类化合物、其制备方法和用途
DK3169815T3 (da) 2014-07-15 2021-02-15 Ontario Institute For Cancer Res Fremgangsmåder og indretninger til forudsigelse af anthracyclinbehandlingseffektivitet
CN107405348B (zh) * 2014-12-23 2021-06-11 点疗法-1公司 Raf抑制剂与紫杉烷的组合
WO2017066664A1 (en) * 2015-10-16 2017-04-20 Millennium Pharmaceuticals, Inc. Combination therapy including a raf inhibitor for the treatment of colorectal cancer
WO2017165742A1 (en) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments
US11760803B2 (en) 2016-03-24 2023-09-19 Takeda Pharmaceutical Company Limited Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
WO2017165491A1 (en) * 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Use of a pd-1 antagonist and a raf inhibitor in the treatment of cancer
CN109053630B (zh) * 2018-08-22 2022-04-01 中国人民解放军第二军医大学 一种苯并噻唑类衍生物及其用途
WO2020097398A1 (en) * 2018-11-07 2020-05-14 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
WO2020232445A1 (en) * 2019-05-16 2020-11-19 The Regents Of The University Of California Modulators of pyrimidine nucleotide biosynthetic pathways
EP4146639A1 (en) 2020-05-06 2023-03-15 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
CN112094248B (zh) * 2020-09-17 2023-05-12 中国人民解放军海军军医大学 一种取代苯并噻唑类化合物及其用途

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2399026A (en) 1941-02-06 1946-04-23 Chem Ind Basel Amides of 2-aminoarylenethiazoles
US4096264A (en) 1975-12-09 1978-06-20 Merck & Co., Inc. Certain substituted imidazo [1,2-a] pyridines
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
NZ503432A (en) 1997-09-26 2002-11-26 Zentaris Gmbh Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function
WO2000042012A1 (en) 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
US7928239B2 (en) 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
EP1158985B1 (en) 1999-01-13 2011-12-28 Bayer HealthCare LLC OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
AU2501600A (en) * 1999-01-13 2000-08-01 Bayer Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
DE60033857T2 (de) 1999-01-22 2007-10-25 Kirin Beer K.K. Derivate des N-((Chinolinyl)oxy)-phenyl)-Harnstoffs und des N-((Chinazolinyl)oxy)-phenyl)-Harnstoffs mit Antitumor Aktivität
EP1193255A4 (en) 1999-07-01 2002-08-07 Ajinomoto Kk HETEROCYCLIC COMPOUNDS AND THEIR APPLICATIONS IN MEDICINE
NZ518028A (en) 1999-11-05 2004-03-26 Astrazeneca Ab Quinazoline derivatives as VEGF inhibitors
JP2003521543A (ja) 2000-02-07 2003-07-15 アボット ゲーエムベーハー ウント カンパニー カーゲー ２−ベンゾチアゾリル尿素誘導体およびそのプロテインキナーゼ阻害剤としての使用
ME00415B (me) 2000-02-15 2011-10-10 Pharmacia & Upjohn Co Llc Pirol supstituisani 2-indol protein kinazni inhibitori
WO2001066539A1 (en) 2000-03-06 2001-09-13 Smithkline Beecham P.L.C. Imidazol derivatives as raf kinase inhibitors
GB0005357D0 (en) 2000-03-06 2000-04-26 Smithkline Beecham Plc Compounds
AU8181701A (en) 2000-06-21 2002-01-02 Hoffmann La Roche Benzothiazole derivatives
CN1471523A (zh) 2000-09-21 2004-01-28 ʷ 咪唑类棉子糖激酶抑制剂
DE60126997T2 (de) 2000-10-20 2007-10-25 Eisai R&D Management Co., Ltd. Stickstoff-enthaltende aromatische ringverbindungen zur behandlung von tumorerkrankungen
JP2004517080A (ja) * 2000-11-29 2004-06-10 グラクソ グループ リミテッド Ｔｉｅ−２および／またはｖｅｇｆｒ−２の阻害剤として有用なベンゾイミダゾール誘導体
GB0112348D0 (en) 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
GB0121488D0 (en) 2001-09-05 2001-10-24 Smithkline Beecham Plc Compounds
US20040192689A1 (en) 2001-09-05 2004-09-30 Dean David Kenneth Heterocycle-carboxamide derivatives as raf kinase inhibitors
GB0121494D0 (en) 2001-09-05 2001-10-24 Smithkline Beecham Plc Compounds
EP1423383B1 (en) 2001-09-05 2008-08-06 Smithkline Beecham Plc Pyridine substituted furan derivatives as raf kinase inhibitors
US7338959B2 (en) 2002-03-01 2008-03-04 Smithkline Beecham Corporation Diamino-pyrimidines and their use as angiogenesis inhibitors
US8299108B2 (en) 2002-03-29 2012-10-30 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of raf kinase
AU2003226211B2 (en) 2002-03-29 2008-05-29 Novartis Vaccines And Diagnostics, Inc. Substituted benzazoles and use thereof as RAF kinase inhibitors
US7893096B2 (en) 2003-03-28 2011-02-22 Novartis Vaccines And Diagnostics, Inc. Use of small molecule compounds for immunopotentiation
US7378233B2 (en) 2003-04-12 2008-05-27 The Johns Hopkins University BRAF mutation T1796A in thyroid cancers
DE10334663A1 (de) 2003-07-30 2005-03-10 Merck Patent Gmbh Harnstoffderivate
DE10337942A1 (de) 2003-08-18 2005-03-17 Merck Patent Gmbh Aminobenzimidazolderivate
DE602004021838D1 (de) 2003-10-16 2009-08-13 Novartis Vaccines & Diagnostic Substituierte benzazole und ihre verwendung als raf-kinase-hemmer
WO2005112932A2 (en) 2004-05-07 2005-12-01 Exelixis, Inc. Raf modulators and methods of use
MX2007001155A (es) 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
KR20060079098A (ko) 2004-12-31 2006-07-05 주식회사 엘지생명과학 신규한([1,3]티아졸로[5,4-ｂ]피리딘-2-일)-2-카르복사마이드유도체
WO2006076376A1 (en) 2005-01-11 2006-07-20 Medicinova, Inc. Topical treatment of solid tumors and ocular neovascularization
BRPI0607307A2 (pt) * 2005-01-26 2009-08-25 Irm Llc compostos e composições como inibidores de proteìna cinase
WO2007007886A1 (en) 2005-07-11 2007-01-18 Mitsubishi Tanabe Pharma Corporation An oxime derivative and preparations thereof
TWI387592B (zh) 2005-08-30 2013-03-01 Novartis Ag 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法
GT200600429A (es) 2005-09-30 2007-04-30 Compuestos organicos
WO2007058482A1 (en) 2005-11-16 2007-05-24 Lg Life Sciences, Ltd. Novel inhibitors of protein kinase
WO2007121484A2 (en) 2006-04-19 2007-10-25 Novartis Ag 6-o-substituted benzoxazole and benzothiazole compounds and methods of inhibiting csf-1r signaling
JPWO2008016131A1 (ja) 2006-08-04 2009-12-24 武田薬品工業株式会社 縮合複素環化合物
CL2007002261A1 (es) 2006-08-04 2008-05-02 Takeda Pharmaceutical Compuestos derivados de imidazo[1,2-b]piridazina, inhibidores de quinasa; composicion farmaceutica; y uso en el tratamiento o prevencion del cancer.
WO2008084873A1 (ja) 2007-01-10 2008-07-17 Mitsubishi Tanabe Pharma Corporation オキシム誘導体
JP4328820B2 (ja) 2007-01-10 2009-09-09 田辺三菱製薬株式会社 医薬組成物
CN101260106A (zh) * 2007-03-06 2008-09-10 中国药科大学 Raf激酶抑制剂及其制备方法和用途
US20100203043A1 (en) 2007-04-13 2010-08-12 Ree Anne H Treatment and diagnosis of metastatic prostate cancer with inhibitors of epidermal growth factor receptor (egfr)
US20110091377A1 (en) 2007-05-11 2011-04-21 The Johns Hopkins University Biomarkers for melanoma
AU2008256922B2 (en) 2007-05-23 2011-07-28 Novartis Ag Raf inhibitors for the treatment of thyroid cancer
CL2008001626A1 (es) 2007-06-05 2009-06-05 Takeda Pharmaceuticals Co Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer.
JP2008307581A (ja) 2007-06-15 2008-12-25 Sanyo Special Steel Co Ltd 管材の洗浄装置
US8324395B2 (en) 2007-08-23 2012-12-04 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
EP2184285B1 (en) 2007-08-29 2015-11-04 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
WO2009028655A1 (ja) 2007-08-30 2009-03-05 Takeda Pharmaceutical Company Limited 複素環化合物およびその用途
JP2009125256A (ja) 2007-11-22 2009-06-11 Kandado:Kk 安眠枕
CN101220024A (zh) * 2007-12-11 2008-07-16 杜晓敏 一组抑制激酶的抗癌化合物
US20110081362A1 (en) 2008-01-31 2011-04-07 The Brigham And Women's Hospital, Inc. Treatment of cancer
US20090275546A1 (en) 2008-04-10 2009-11-05 Istituto Superiore Di Sanita Diagnostic tests and personalized treatment regimes for cancer stem cells
US8445509B2 (en) 2008-05-08 2013-05-21 Takeda Pharmaceutical Company Limited Fused heterocyclic derivatives and use thereof

Also Published As

Publication number Publication date
MX2011005836A (es) 2011-06-17
CA2745144A1 (en) 2010-06-10
US8497274B2 (en) 2013-07-30
CO6400140A2 (es) 2012-03-15
IL213184A0 (en) 2011-07-31
ZA201104659B (en) 2012-08-29
EA201170735A1 (ru) 2011-12-30
AU2009323274A1 (en) 2011-07-07
ME02331B (me) 2016-04-28
HUE026491T4 (en) 2017-07-28
GEP20146003B (en) 2014-01-10
US20120214855A1 (en) 2012-08-23
SI2358689T1 (sl) 2016-01-29
PL2358689T3 (pl) 2016-03-31
MY150989A (en) 2014-03-31
WO2010064722A1 (en) 2010-06-10
NZ593759A (en) 2012-07-27
UY32281A (es) 2010-06-30
EP2358689A1 (en) 2011-08-24
AU2009323274B2 (en) 2015-09-17
SG171426A1 (en) 2011-07-28
CL2011001299A1 (es) 2012-01-13
KR20110091039A (ko) 2011-08-10
ES2557304T3 (es) 2016-01-25
HK1161236A1 (zh) 2012-08-24
MA32911B1 (ar) 2011-12-01
CA2745144C (en) 2017-10-03
SMT201500316B (it) 2016-01-08
CY1117178T1 (el) 2017-04-05
AR074435A1 (es) 2011-01-19
TN2011000280A1 (en) 2012-12-17
RS54370B9 (sr) 2020-01-31
HRP20151370T1 (hr) 2016-01-15
TWI436987B (zh) 2014-05-11
CN102300854B (zh) 2015-01-07
DK2358689T5 (en) 2016-10-10
DOP2011000165A (es) 2011-06-30
EA019447B1 (ru) 2014-03-31
CR20110366A (es) 2011-08-29
PE20110588A1 (es) 2011-09-08
EP2358689B9 (en) 2016-08-03
US8143258B2 (en) 2012-03-27
TW201024272A (en) 2010-07-01
DK2358689T3 (en) 2015-12-14
PT2358689E (pt) 2015-12-30
US20100216810A1 (en) 2010-08-26
JP5640014B2 (ja) 2014-12-10
BRPI0922109A2 (pt) 2020-09-01
ECSP11011165A (es) 2011-07-29
JP2012510467A (ja) 2012-05-10
EP2358689B1 (en) 2015-09-30
RS54370B1 (en) 2016-04-28
KR101639092B1 (ko) 2016-07-12
HUE026491T2 (en) 2016-06-28
CN102300854A (zh) 2011-12-28

Similar Documents

Publication Publication Date Title
JO3101B1 (ar) مشتقات بنزوثيازول كعوامل مضادة للسرطان
MY158982A (en) Heterocyclic compound
WO2009028629A1 (ja) 複素環化合物およびその用途
WO2009025358A1 (ja) 複素環化合物およびその用途
TN2010000101A1 (en) Fungicidal 2-alkylthio-2-quinolinyloxy -acetamide derivatives
MY156319A (en) Spiroheterocyclic n-oxypiperidines as pesticides
PH12014502396A1 (en) Nitrogenated heterocyclic compound
EP2657233A4 (en) 3,5-DISUBSTITUTED ALKYNYLBENZENE COMPOUND AND SALT THEREOF
PH12014501719B1 (en) Pyridone derivatives
MX2010002244A (es) Nuevos fungicidas.
MX2014002254A (es) Derivados de benzotiofeno piperazina sustituidos como agentes antipsicoticos.
EA201000544A1 (ru) Производные спирогетероциклического пирролидиндиона, применимые в качестве пестицидов
WO2008110355A8 (en) Quinoline derivatives as fungicides
BRPI0914772A2 (pt) compostos heterocíclicos 1,2-dissubstituídos
EA201290800A1 (ru) Гетероциклическое соединение
IN2015DN01035A (ar)
MX347562B (es) Derivados fungicidas de 3-fenil[(heterociclilmetoxi)imino]metil}-1 ,2,4-oxadiazol-5(4h)-ona sustituidos en 4.
MY163187A (en) Novel imidazo-oxazine compound or salt thereof
MY157497A (en) Pyrazinooxazepine derivatives
GB201305247D0 (en) Amide Compounds
GT200700074A (es) Fungicidas
PH12015501146A1 (en) Hydantoin derivative
MX2013003749A (es) Derivados de 1,4-oxazepano.
WO2008108309A1 (ja) 縮環ピリジン誘導体
UA106059C2 (uk) Похідні бензотіазолу як агенти проти раку